EUVIMEDEUVIMED entdecken
Crossref

Immune-checkpoint inhibitor-induced colitis in a patient with lung cancer

Wei Liu

Journal of Clinical Surgery and Research · 2021

DOI: 10.31579/2768-2757/015 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Surgery and Research, 2021. Verfasst von Wei Liu.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A 62-year-old man was hospitalized in the emergency room because of severe and persistent abdominal pain with bloody diarrhea (14 stools per day over baseline). He had peritoneal signs, with severe periumbilical tenderness and active bowel sounds. Computed tomography of the abdomen revealed thickened wall of the colon. Laboratory evaluation revealed a hemoglobin level of 11.5 g per deciliter (normal range, 13.5 to 17.5). For the previous 4 weeks, the patient had been taking the immune-checkpoint inhibitor toripalimab (targeting programmed death 1, 240 mg once daily) for small-cell lung cancer. Stool tests for Clostridioides difficile infection and other gastrointestinal pathogens yielded negative results. A colonoscopy revealed numerous erosions/ulcers with marked erythema, absent vascular pattern, and friability (Figure A). Biopsy specimens from the colon confirmed severe inflammatory changes, well differentiated glands, crypt abscess, diffuse inflammatory cell infiltration and plasma cell aggregation

Zitieren

APA

Liu, W. (2021). Immune-checkpoint inhibitor-induced colitis in a patient with lung cancer. Journal of Clinical Surgery and Research. https://doi.org/10.31579/2768-2757/015

Vancouver

Liu W. Immune-checkpoint inhibitor-induced colitis in a patient with lung cancer. Journal of Clinical Surgery and Research. 2021. doi:10.31579/2768-2757/015

BibTeX
@article{Liu2021,
  author = {Liu, Wei},
  title = {Immune-checkpoint inhibitor-induced colitis in a patient with lung cancer},
  journal = {Journal of Clinical Surgery and Research},
  year = {2021},
  doi = {10.31579/2768-2757/015}
}
Kostenlos starten →